Ocular Therapeutix Inc. (0OT)
XSTU 
Summary
0OT Chart
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.5% – Time to Buy?
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report)'s share price was up 9.5% during mid-day trading on Friday. The stock traded as high as $7.20 and last traded at $7.6970. Approximately 504,364 shares were traded during trading, a decline of 92% from the average daily volume of 6,703,719 shares. The stock had previously closed
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago.
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ocular Therapeutix Inc. (0OT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Ocular Therapeutix Inc. ever had a stock split?
Ocular Therapeutix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Pravin U. Dugel M.D. CEO | XSTU Exchange | US67576A1007 ISIN |
| US Country | 325 Employees | - Last Dividend | - Last Split | 25 Jul 2014 IPO Date |
Overview
Ocular Therapeutix, Inc. is a progressive biopharmaceutical entity with a dedicated focus on crafting, developing, and commercializing innovative therapies for eye diseases and conditions. Leveraging its proprietary bioresorbable hydrogel-based formulation technology, the company is at the forefront of addressing significant unmet medical needs in ophthalmology in the United States. Its collaboration with industry leaders such as Regeneron Pharmaceuticals, Inc. and AffaMed Therapeutics Limited underscores its commitment to advancing ophthalmic care through sustained-release hydrogel solutions and enhanced drug delivery systems. Founded in 2006, Ocular Therapeutix has established its headquarters in Bedford, Massachusetts, marking a significant presence in the biopharmaceutical sector with its groundbreaking approach to eye care.
Products and Services
- DEXTENZA
A cornerstone of Ocular Therapeutix's market offerings, DEXTENZA is an FDA-approved dexamethasone ophthalmic insert designed for the treatment of post-surgical ocular inflammation and pain following ophthalmic surgery. Additionally, it is indicated for the treatment of allergic conjunctivitis. DEXTENZA represents a leap forward in ocular pain management and inflammation control, providing sustained relief through a bioresorbable hydrogel-based insert.
- AXPAXLI
Currently in phase 3 trials, AXPAXLI is an axitinib intravitreal implant developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. AXPAXLI exemplifies Ocular Therapeutix's commitment to addressing the challenges of AMD, a leading cause of vision loss, through innovative, sustained-release drug delivery technologies.
- PAXTRAVA
PAXTRAVA, a travoprost intracameral implant, is undergoing phase 2 clinical trials. It is aimed at treating open-angle glaucoma or ocular hypertension by offering a novel, sustained-release solution to reduce intraocular pressure, a key factor in the progression of glaucoma.
- OTX-CSI
Having completed phase 2 clinical trials, OTX-CSI is a cyclosporine intracanalicular insert designed for the treatment of dry eye disease. OTX-CSI represents an innovative approach to managing dry eye symptoms by providing sustained cyclosporine delivery directly to the ocular surface.
- OTX-DED
In phase 2 clinical trials, OTX-DED is a dexamethasone intracanalicular insert developed for the short-term treatment of the signs and symptoms of dry eye disease. This offering highlights Ocular Therapeutix's dedication to improving patient outcomes in dry eye management through its proprietary hydrogel technology.
- Gene Delivery & Protein Biofactory
The company is also engaged in developing gene delivery solutions for inherited retinal degenerations and leveraging its platform as a protein biofactory for various indications. These frontier areas of research have the potential to offer transformative treatments for complex ophthalmic diseases.
